As in breast cancer, in the context of gynecologic malignancies (such as ovarian cancer, endometrial cancer and cervical cancer), SIRT1 has been implicated in both tumor suppression and tumor progression, depending on the cellular context. Here, SIRT1 is linked to endometrial cancer.